Development of microRNA amplifier to regulate cell-mediated immune responses

Research Project

Project/Area Number	26861144
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Neurosurgery
Research Institution	Nagoya University
Principal Investigator	Nishimura Yusuke 名古屋大学, 医学部附属病院, 講師 (20447816)
Project Period (FY)	2014-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000) Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords	脊髄損傷 / ベバシズマブ / 血管内皮細胞増殖因子 / 炎症性浮腫 / 反応性アストロサイト / 二次損傷 / regulatory T cell / マイクロRNA / CTLA4-Ig / VEGF
Outline of Final Research Achievements	Bevacizumab, an anti-VEGF monoclonal antibody, has been proposed as treatment for gliomas and radiation necrosis in the neurological field. In our study using spinal cord injury (SCI) mice, bevacizumab has been shown to alleviate focal inflammation and edema due to suppressed vascular hyper-permeability in the acute phase of secondary injury, leading to improvement of neurological function. Our results indicate that bevacizumab may become a promising drug for alleviating SCI.

Report

(3 results)